Comparison of the the Efficacy and Safety of durable polymer Novolimus-eluting Elixir DESyne X2™ Stent with Bioresorbable Polymer Sirolimus-Eluting Orsiro™ Stent in a Real World” patient population

Koera University Guro Hospital0 个研究点目标入组 1,176 人开始时间: 待定最近更新: 2022年10月24日

试验速览

暂无简介。

•1) Patient over 20 years old
•2) Those who have objective ischemia symptoms such as Stable MI, Unstable MI, Acute or Recent MI or have objective evidence suggesting ischemia by electrocardiogram or functional tests (However, if coronary artery stenosis is more than 70%, no mention of objective ischemia is required)
•3) RVD 2.5-4.0mm, Lesion that could be treated with stents.
•4) One or more epicardial coronary artery stenosis (above 50%)
•5) Patient who agree to sign on ICF.

•1) Patient with cardiogenic shock or SBP less than 80 mmHg.
•2) Persons with known hypersensitivity or contraindications to the following drugs and substances: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Biolimus A9, Novolimus, Stainless steal, Cobalt chromium, Contrast agent (However, even subjects with hypersensitivity to contrast agents could be registered if they could be controlled by steroids and pheniramine, but those with known anaphylaxis are excluded.)
•3) Lactating and pregnant women. Women who wish to participate other clinical trials.
•4) Patient who life expectancy is less than 1 year
•5) Patients who disagree to participate in this clinical trial.

发起方

Koera University Guro Hospital